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ABSTRACT
Obesity leads to premature death and impairs quality of life. In general, weight loss is responsible and reduced the risk of cardiovascular disease that is 
associated with obesity. One of the recognized and well-establishment treatment options for weight loss, i.e., pharmacotherapy, where cardiovascular 
safety issues with some previous weight loss drugs raise concerns for newly approved pharmacotherapies. Previously, number of anti-obesity drugs 
that are already withdrawn from the market because of adverse side effects. In the present study, our group focused only on anti-obesity drugs that 
are currently under investigation and also understand its pathogenesis. Although lot of anti-obesity drugs are in the pipeline, the process for getting 
such type of drugs to be marketed has recently proven so difficult.
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INTRODUCTION
One of the major global health problems, i.e., obesity, has been growing 
worldwide. Around 1.5 billion overweight and 500 million obese 
individuals were reported [1,2]. Hence, overweight and obesity are 
included as risk factor for causing major diseases, i.e., cardiovascular 
disease including diabetes and cancer [2-5]. In an effort to regulate 
the body weight pertaining to reduce the burden of this disease, 
i.e., obesity, scientists focused on neuropeptides and transmitters that 
are widely used in brain circuits and provide signals to endocrine and 
metabolic system [6]. Now-a-day, major target, i.e., brain circuits and 
tried to prepare or synthesize new pharmaceutical drugs that are 
beneficial for the treatment of obesity [6]. Recently, the Food and Drug 
Administration (FDA) approved two anti-obesity drugs (e.g., lorcaserin 
and Qsymia) pertaining to reduce the burden of cardiovascular disease 
[6-8]. Previous drugs related to obesity were rejected or removed 
because of various side effects observed in various cardiovascular 
organs [6-8]. In brain, variety of neuropeptides and transmitters that 
are present and performed various steps (i.e., initiation, termination, 
and choice) for energy uptake and these signals are received through 
endocrine factors and peripheral nerves [7-9]. These signals that are 
transmitted through various metabolic systems including endocrine 
system showed enormous potential for the development of weight 
loss drugs [7-9]. Previously, a number of drugs are approved, for 
example, amphetamines and sibutramine. Recently, newly approved 
drugs, i.e., lorcaserin, Qsymia, tesofensine, and contrave-targeted 
monoaminergic systems.
Generally, obesity is associated with number of chronic conditions 
such as heart failure, type 2 diabetes, coronary artery disease, and 
osteoarthritis. [10]. This disease is normally reported worldwide and 
almost all the countries are facing the problem of obesity and showed lot 
of variation within or outside the country. These variations are generally 
because of lifestyle and high-fat diets that are increased globally [10]. 
Changes in dietary content and physical activity are often the result of 
environmental and societal changes that are linked with development 
but lack of supported policies such as health, agriculture, environment, 
food processing, marketing, and education. According to the National 
Health and Nutrition Examination Survey in year 2011-2012, it showed 
that 33.9% population are overweight (age more than 20), 35.1% 
obese, and 6.4% are extremely obese. These calculations were done on 
the basis of heights and weights of individual person and these studies 
were conducted in the US. In addition, overweight, obesity, and extreme 
obesity were classified [11] in the form of body mass index (BMI) which 
is expressed in kg/m2. Normally, BMI (Fig. 1) should be in the range of 
overweight (25.0-29.9), obesity (≥30.0), and extreme obesity (≥40.0).
To reduce the burden, many medications were used and some of them 
were approved as anti-obesity drug but later on withdraw from the 
market [11] because of serious adverse effects. Some of them are:
• Fenfluramine and dexfenfluramine (heart valve damage; 1990’s)
• Phentermine, diethylpropion, and mazindol (2000’s)
• Selective cannabinoid 1 receptor blocker, i.e., rimonabant (2009, FDA 
never approved because of side effects, e.g., depression and anxiety).
• Sibutramine (2010; increased cardiovascular events and strokes)
• Bupropion/naltrexone combination, i.e., Contrave (2011; potential 
cardiovascular risks).
In addition, number of preventive measures also be taken for obesity 
and is generally reported in infants and young children. Most of 
the preventive strategies related to obesity [10] that are included, 
i.e., avoiding use of added sugar when feeding infants; appropriate 
micronutrients including fruits and vegetables are needed to promote 
the growth of children; and restriction of soft drinks. In contrast, apart 
from preventive measures of obesity, our group focused on various 
medications related to its risks, complications, and most importantly 
drugs that are available for the treatment of obesity including several 
newer treatments currently being investigated.
MECHANISM IN THE PATHOGENESIS OF OBESITY
There may be several mechanisms that are involved in the development 
of obesity which is generally associated with various dysfunctions. 
Generally, obesity is associated with:
a. Enhancement in production of reactive oxygen species (ROS; limits 
the bioavailability of nitric oxide [NO] through diminished NO 
production and direct inactivation of NO by superoxide, O2−) [12,13]
b. In muscle and kidney, endothelial nitric oxide synthase expression 
and its activity are totally diminished in obesity resulting in blunted 
NO production [14]
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d. Elevation in fatty acid induces phosphorylation of insulin receptor-
mediated phosphorylation (IRS-1). These fatty acids tried to 
interfere with IRS-1 and in turn results in impaired activation of 
PI3-kinase [16].
In addition, adipose tissue not only functions as passive storage depot but 
also may be reported as a highly active endocrine organ. Adipose tissue 
including visceral adipocytes secretes a variety of immunologically 
bioactive molecules called adipokines. In case of obesity, there is an 
enhanced production of free fatty acids, angiotensinogen, leptin, resistin 
including several pro-inflammatory cytokines, i.e., tumor necrosis 
factor (TNF)-α and interleukin-6 (IL-6), whereas the production rate of 
adiponectin including anti-inflammatory adipokine is inhibited [17,18].
Among wide varieties of cytokines release by T-helper cells (Th1/
Th2) or produced by adipose tissue, a more recent and less studied 
adipocytokine, i.e., anti-inflammatory cytokine IL-1 receptor antagonist 
(IL-1Ra). The key points of IL-1 Ra [19,20] are:
• Unprocessed or chemical free antagonist to the proinflammatory 
cytokine IL-1 and acts by binding to IL-1 receptors without inducing 
a cellular response
• Plasma IL-1Ra levels are elevated in human obesity and reduced 
after bariatric surgery
• Human adipose tissue appears to be a major source of plasma IL-1Ra 
and its expression in this tissue is markedly increased in obesity
• Plasma IL-1Ra levels are strongly correlated with insulin resistance.
We, therefore, explore the association between plasma elevation of 
IL-1Ra and abdominal adipose tissue depots measured by computed 
tomography. Our study revealed that circulating IL-1Ra concentrations 
were regulated or transformed to a greater extent by intra-abdominal 
than subcutaneous adiposity. We also found that plasma concentration 
of IL-1Ra levels increased with the number of metabolic abnormalities. 
Furthermore, scientists also reported and observe the association 
between IL-1Ra levels and several cardiometabolic risk variables 
which appeared to be partly independent from the variation in intra-
abdominal adiposity.
In addition, cytokines, especially plasma TNF-α values, do not provide 
accurate information about the mechanism of action related to obesity. 
sTNFR2 (soluble TNF receptor) is more stable protein as compared 
to sTNFR1, and therefore, it may proposed that sTNFR2 should be a 
better diagnostic marker for TNF-α system activation in case of obese 
individuals with TNF-related insulin resistance [21,22]. Both the 
receptors of TNF-α are expressed in human adipose tissue and number 
of studies also claimed that TNFR2 could played a crucial role in the 
induction of insulin resistance. In other words, sTNFR2 levels are more 
closely related to abdominal adipose tissue accumulation and stronger 
independent marker of insulin resistance than TNF-α even after 
controlling for intra-abdominal adipose tissue [21-23].
EXAMPLES OF ANTI-OBESITY DRUGS THAT ARE CURRENTLY 
UNDER INVESTIGATION
Geographically, anti-obesity drugs’ markets are present globally and 
these are segmented into North America, Europe, Asia Pacific, Latin 
America, and rest of the world. Recently, North America is number one 
shareholder for this market because of increased obese population. As 
per the reports of Centers for Disease Control and Prevention, more 
than one-third of the U.S population is reported in 2014 as obese. 
However, Asia Pacific is more expected to grow at much higher rate due 
to over demand of drugs and also increased its awareness related to 
risk associated with obesity. In addition, unhealthy diet would expect 
to enhance the number of obese people during forecast period. In 
this aspect, number of anti-obesity drugs that are currently under 
investigation:
Lorcaserin (approved in 2012; US FDA; Fig. 2), chemical entity that 
is able to activate serotonin 2C receptors in the brain. Because of this 
activation, these receptors are responsible for providing help and feel 
full after eating less quantity of food. The most common symptoms are 
observed in multiple Phase III clinical studies and are reported in both 
non-diabetic (headache, fatigue, nausea, dry mouth, and constipation) 
and diabetic (hypoglycemia, headache, back pain, cough, and fatigue) 
patients. This drug is called by different names, i.e., Belviq (US brand) 
and Venespri (Lorcaserin; Mexico brand) [24-26]. This drug is rapidly 
or quickly absorbed in gastrointestinal tract and is evenly distributed in 
central nervous system and cerebrospinal fluid. The major metabolite, 
i.e., lorcaserin sulfamate that is present in lorcaserin (70% plasma 
protein bound and metabolized in liver) and its excretion, is generally 
Fig. 1: Obesity and risk factors; overweight and obesity prevalence by age and sex; obesity rate in children (ages 6-11); and classification 
on the basis of body mass index including distribution rate in European countries. In addition, IAP, WHO, and IOTF data included for year 
2000, 2007, and 2015 in Gujarat, India
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through urine (92%) and minor excretion through faces. Most of 
the drugs that directly interfere with serotonin neurotransmission, 
i.e., selective serotonin reuptake inhibitors, serotonin norepinephine 
reuptake inhibitor, and monoamine oxidase inhibitors that generally 
lead to serotonin syndrome (symptoms such as increase in blood 
pressure, shivering, and sweating) [27,28]. In addition, this drug showed 
some enhancement in prolactin levels and is more contraindicated in 
case of pregnancy as weight loss cannot be able to monitor. This study 
is not reported and studied in patients below 18 years, so pediatric data 
are not available. Hence, no dose adjustment is required with mild to 
moderate renal and hepatic diseases [26-30].
• Phentermine and topiramate firstly approved by the FDA in year 
2010; however, later on, this drug will reject because of adverse 
side effects such as heart beat rate increased, teratogenicity, and 
suicidality. Again in the year, i.e., 2010, the FDA wants additional data 
from Vivus (manufacturer) [9]. In 2012, again FDA recommended 
approval of phentermine and topiramate with some drastic changes 
from the previous ones and approved as a schedule intravenous drug 
under the brand name, Qsymia. This drug is more expected to treat 
number of obese patients (Basal metabolic rate, BMI ≥35 kg/m2) 
or patients with obesity (BMI ≥30 kg/m2) who have weight-related 
health problems, such as high blood pressure, type 2 diabetes, or 
abnormal levels of fat in the blood [31,32]. In Qsiva, the presence 
of two active substances and they are   regarded as appetite 
suppressants. Functionally, phentermine suppresses appetite and is 
generally through chemical transmitter that are released and called 
as norepinephrine (or noradrenaline) in the hypothalamus (region of 
the brain that controls hunger), whereas topiramate is thought to act 
by increasing the body’s energy use, reducing energy efficiency, and 
reducing the patients’ appetite for food. In addition to weight loss, 
phentermine and topiramate resulted in improved comorbidities 
and quality of life although not be able to shown or improve mental 
issues. Among the most common adverse events that are observed in 
clinical trials, i.e., paresthesia, dry mouth, constipation, and headache 
(Fig. 3) [31,32].
• Tesofensine (Fig. 4) is reported as anti-obesity drug and showed 
substantial weight loss in obese individuals. Drug development in 
the field of weight disorder has regularly faced pharmacovigilance 
hurdles [2,8,9] because anorexigenic drugs affect various systems 
(sympathetic, serotoninergic, etc.) and thus lead or showed adverse 
reactions as well as the expected pharmacodynamic effect.
• Orlistat, gastrointestinal lipase inhibitor, approved by FDA in 1999; 
however, in year 2007, this drug withdraws from the market because 
of adverse effects [33]. Recently, cetilistat, novel, orally active, 
gastrointestinal, and pancreatic lipase inhibitor. In vitro studies 
claimed that cetilistat inhibited human pancreatic lipase with an 
IC50 in the low nanomolar range. In phase II, clinical trials in obese 
patients and also observed in obese patients along with Type 2 
diabetes, cetilistat administered for 12 weeks significantly reduced 
body weight, serum low-density lipoprotein cholesterol, and total 
cholesterol in comparison to placebo (Fig. 5).
• In February 2016, Health Canada approved first new anti-obesity 
drug for Canadian in nearly two decades. Most of the Canadians are 
looking for medical treatment related to obesity and two prescription 
drugs are now available to them, i.e., first of them old anti-obesity 
drug, orlistat (Xenical; works by inhibiting fat digestion and reduced 
lot of calories absorbed from fat in the gut) and new one liraglutide 
Fig. 2: Lorcaserin
Fig. 3: Phentermine and topiramate Fig. 5: Orlistat
Fig. 4: Tesofensine
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(Saxenda; close analog to human glucagon-like peptide 1, gut 
hormone that played a key role in insulin secretion and appetite 
regulation).
CONCLUSION
Now-a-day, obesity has a rapid increment or enhancement leading to 
increased risk of various cardiovascular diseases (e.g., diabetes) and 
mortality ratio will increase year by year. In obesity, body weight is 
included under surrogate marker, but it cannot be able to predict the 
efficacy of drug samples clinically. Expectations from the researchers 
or scientists are more pertaining to anti-obesity drugs with no adverse 
effects after consuming. Till now, no anti-obesity agent has shown such 
type of clinical benefits but many anti-obesity drugs under development 
are the targeting of endogenous endocrine circuits regulating energy 
homeostasis. Overall, our group focused only on obesity and tried to 
support public health policy makers and practitioners. This paper 
provides some information about pathogenesis and provides available 
data related to anti-obesity drugs and evidence illustrate the prevalence 
trends in obesity and various cardiovascular diseases at a national and 
international level as well as the potential implications in terms of 
health consequences, inequalities, and cost.
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